

**REMARKS/ARGUMENTS**


In the Advisory Action dated September 19, 2002, the Examiner indicated that the proposed Amendment to claim 13 continues to have vague and indefinite language, namely "corresponding to" which would necessitate new grounds of rejection under 35 USC 112 and hence the Amendment after Final submitted May 13, 2002, would not be entered.

By this Amendment in this RCE filing, claim 13 has been further amended to replace the term "corresponding to" with "which is". It is submitted that the substitute language cannot be considered indefinite and that claims 13 to 15 are now in an allowable form along with claim 12.

Reconsideration of the rejection of claims 1 and 4 to 11 under 35 USC 112, first paragraph, is requested having regard to the submission made in the Amendment after Final submitted May 13, 2002.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned **"Version with markings to show changes made."**

Respectfully submitted,

  
Michael I. Stewart  
Reg. No. 24,973

Toronto, Ontario, Canada,  
(416) 595-1155  
FAX No. (416) 595-1163

Appl. No. 09/055,744

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the Claims:**

Claim 13 has been amended as follows:

13. (Twice Amended) A peptide consisting of an amino acid sequence which is [corresponding to] amino acids 52 to 116 (SEQ ID No: 9) of the sequence of the Rev protein of HIV-1 LAI isolate and containing T-cell epitopes within amino acids 63 to 73 (SEQ ID No: 3), 74 to 83 (SEQ ID No: 5) and 102 to 110 (SEQ ID No: 8), said peptide being in the form of a lipopeptide.